Want to see HK:1652 full AI Analyst Report?
Fusen Pharmaceutical Co., Ltd. (1652) Ratios
0 Followers
Fusen Pharmaceutical Co., Ltd. Ratios
HK:1652's free cash flow for Q2 2026 was ¥-10.09M. For the 2026 fiscal year, HK:1652's free cash flow was decreased by ¥-5.04M and operating cash flow was ¥-5.04M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.56 | 0.60 | 0.85 | 0.85 | 1.04 |
| Quick Ratio | 0.45 | 0.42 | 0.58 | 0.70 | 0.79 |
| Cash Ratio | 0.10 | 0.03 | 0.05 | 0.18 | 0.17 |
| Solvency Ratio | 0.03 | -0.18 | -0.00 | -0.00 | 0.07 |
| Operating Cash Flow Ratio | 0.14 | 0.17 | -0.11 | 0.15 | 0.10 |
| Short-Term Operating Cash Flow Coverage | 0.38 | 0.44 | -0.31 | 0.48 | 0.28 |
| Net Current Asset Value | ¥ -396.11M | ¥ -410.19M | ¥ -214.72M | ¥ -123.32M | ¥ -73.17M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.26 | 0.31 | 0.26 | 0.17 | 0.19 |
| Debt-to-Equity Ratio | 0.90 | 1.04 | 0.61 | 0.37 | 0.37 |
| Debt-to-Capital Ratio | 0.47 | 0.51 | 0.38 | 0.27 | 0.27 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.18 | 0.16 | 0.00 | 0.10 |
| Financial Leverage Ratio | 3.52 | 3.35 | 2.38 | 2.20 | 1.88 |
| Debt Service Coverage Ratio | 0.02 | -0.12 | 0.05 | 0.19 | 0.27 |
| Interest Coverage Ratio | -0.08 | -3.58 | 1.59 | 1.27 | 6.32 |
| Debt to Market Cap | 0.61 | 0.69 | 0.38 | 0.24 | 0.32 |
| Interest Debt Per Share | 0.47 | 0.54 | 0.49 | 0.32 | 0.32 |
| Net Debt to EBITDA | 20.83 | -9.28 | 16.33 | 2.01 | 2.86 |
| Profitability Margins | |||||
| Gross Profit Margin | 40.16% | 49.88% | 52.95% | 45.76% | 54.75% |
| EBIT Margin | -9.46% | -20.60% | -2.98% | -3.78% | 8.31% |
| EBITDA Margin | 4.22% | -11.98% | 3.35% | 10.15% | 14.47% |
| Operating Profit Margin | -0.63% | -20.71% | 3.54% | 3.20% | 13.52% |
| Pretax Profit Margin | -2.78% | -58.41% | -5.21% | -6.30% | 6.17% |
| Net Profit Margin | -4.31% | -57.90% | -6.41% | -7.05% | 4.32% |
| Continuous Operations Profit Margin | -4.32% | -57.91% | -6.42% | -7.05% | 4.31% |
| Net Income Per EBT | 154.99% | 99.13% | 123.19% | 111.81% | 69.96% |
| EBT Per EBIT | 441.78% | 282.10% | -147.12% | -196.93% | 45.63% |
| Return on Assets (ROA) | -0.93% | -15.25% | -2.70% | -2.57% | 1.34% |
| Return on Equity (ROE) | -3.28% | -51.07% | -6.44% | -5.64% | 2.53% |
| Return on Capital Employed (ROCE) | -0.44% | -14.50% | 2.95% | 2.51% | 6.95% |
| Return on Invested Capital (ROIC) | -0.24% | -8.69% | 2.18% | 1.83% | 3.95% |
| Return on Tangible Assets | -0.95% | -15.60% | -2.75% | -3.05% | 1.63% |
| Earnings Yield | -2.22% | -33.95% | -4.03% | -3.63% | 2.14% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.24 | 2.86 | 3.08 | 1.99 | 2.45 |
| Payables Turnover | 1.31 | 1.32 | 1.59 | 1.63 | 1.71 |
| Inventory Turnover | 1.67 | 1.19 | 1.44 | 2.41 | 1.43 |
| Fixed Asset Turnover | 0.50 | 0.52 | 1.01 | 1.56 | 1.35 |
| Asset Turnover | 0.22 | 0.26 | 0.42 | 0.36 | 0.31 |
| Working Capital Turnover Ratio | -0.79 | -1.59 | -5.50 | -11.17 | 5.81 |
| Cash Conversion Cycle | 102.35 | 157.91 | 141.25 | 111.00 | 190.40 |
| Days of Sales Outstanding | 162.91 | 127.49 | 118.41 | 183.47 | 149.14 |
| Days of Inventory Outstanding | 218.90 | 306.23 | 252.66 | 151.41 | 254.82 |
| Days of Payables Outstanding | 279.46 | 275.81 | 229.81 | 223.89 | 213.56 |
| Operating Cycle | 381.81 | 433.72 | 371.06 | 334.88 | 403.95 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.16 | 0.18 | -0.10 | 0.15 | 0.06 |
| Free Cash Flow Per Share | 0.09 | 0.08 | -0.22 | 0.11 | -0.08 |
| Dividend Paid and CapEx Coverage Ratio | 2.35 | 1.75 | -0.83 | 3.58 | 0.40 |
| Capital Expenditure Coverage Ratio | 2.35 | 1.75 | -0.83 | 4.63 | 0.43 |
| Operating Cash Flow Coverage Ratio | 0.38 | 0.35 | -0.21 | 0.48 | 0.20 |
| Operating Cash Flow to Sales Ratio | 0.45 | 0.41 | -0.13 | 0.22 | 0.12 |
| Free Cash Flow Yield | 13.17% | 10.33% | -17.97% | 9.07% | -8.02% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -45.19 | -2.95 | -24.83 | -27.55 | 46.69 |
| Price-to-Sales (P/S) Ratio | 1.94 | 1.71 | 1.59 | 1.94 | 2.02 |
| Price-to-Book (P/B) Ratio | 1.48 | 1.50 | 1.60 | 1.55 | 1.18 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 7.59 | 9.68 | -5.56 | 11.02 | -12.46 |
| Price-to-Operating Cash Flow Ratio | 4.36 | 4.16 | -12.28 | 8.64 | 16.27 |
| Price-to-Earnings Growth (PEG) Ratio | 0.48 | -0.01 | -2.71 | 0.08 | -0.60 |
| Enterprise Value Multiple | 66.84 | -23.51 | 63.91 | 21.14 | 16.78 |
| Enterprise Value | 771.70M | 918.63M | 1.21B | 1.05B | 936.83M |
| EV to EBITDA | 66.84 | -23.51 | 63.91 | 21.14 | 16.78 |
| EV to Sales | 2.82 | 2.82 | 2.14 | 2.15 | 2.43 |
| EV to Free Cash Flow | 11.03 | 16.00 | -7.48 | 12.18 | -15.02 |
| EV to Operating Cash Flow | 6.33 | 6.87 | -16.50 | 9.55 | 19.61 |
| Tangible Book Value Per Share | 0.47 | 0.46 | 0.74 | 0.53 | 0.57 |
| Shareholders’ Equity Per Share | 0.49 | 0.50 | 0.78 | 0.81 | 0.86 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.55 | 0.01 | -0.23 | -0.12 | 0.30 |
| Revenue Per Share | 0.37 | 0.44 | 0.78 | 0.65 | 0.50 |
| Net Income Per Share | -0.02 | -0.26 | -0.05 | -0.05 | 0.02 |
| Tax Burden | 1.55 | 0.99 | 1.23 | 1.12 | 0.70 |
| Interest Burden | 0.29 | 2.84 | 1.75 | 1.67 | 0.74 |
| Research & Development to Revenue | 0.05 | 0.33 | 0.14 | 0.03 | 0.03 |
| SG&A to Revenue | 0.30 | 0.43 | 0.13 | 0.14 | 0.17 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -10.62 | -0.70 | 2.49 | -3.56 | 2.01 |
Currency in CNY
